Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Consensus Rating of “Moderate Buy” by Brokerages

Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Rating) has earned an average rating of “Moderate Buy” from the fifteen brokerages that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $104.64.

A number of equities analysts recently weighed in on AXSM shares. Mizuho reaffirmed a “buy” rating and issued a $84.00 price target on shares of Axsome Therapeutics in a report on Monday, March 13th. Piper Sandler started coverage on Axsome Therapeutics in a report on Thursday, January 5th. They issued a “neutral” rating and a $75.00 price target for the company. Guggenheim reduced their price target on Axsome Therapeutics from $105.00 to $90.00 and set a “buy” rating for the company in a report on Tuesday, February 28th. Morgan Stanley reduced their price target on Axsome Therapeutics from $86.00 to $85.00 and set an “equal weight” rating for the company in a report on Tuesday, February 28th. Finally, BTIG Research increased their target price on Axsome Therapeutics from $62.00 to $98.00 and gave the company a “buy” rating in a report on Friday, December 23rd.

Axsome Therapeutics Stock Down 0.8 %

Shares of AXSM opened at $62.74 on Friday. Axsome Therapeutics has a 52 week low of $20.63 and a 52 week high of $82.00. The company has a quick ratio of 2.50, a current ratio of 2.54 and a debt-to-equity ratio of 0.86. The company has a market capitalization of $2.73 billion, a price-to-earnings ratio of -13.73 and a beta of 1.95. The stock’s 50-day moving average price is $66.01 and its 200-day moving average price is $61.97.

Axsome Therapeutics (NASDAQ:AXSM – Get Rating) last released its quarterly earnings results on Monday, February 27th. The company reported ($1.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.10). The company had revenue of $24.37 million during the quarter, compared to the consensus estimate of $21.51 million. On average, sell-side analysts predict that Axsome Therapeutics will post -4.52 EPS for the current year.

Institutional Trading of Axsome Therapeutics

Several large investors have recently added to or reduced their stakes in AXSM. Captrust Financial Advisors raised its holdings in shares of Axsome Therapeutics by 582.0% during the 1st quarter. Captrust Financial Advisors now owns 757 shares of the company’s stock worth $31,000 after acquiring an additional 646 shares during the period. Armstrong Advisory Group Inc. purchased a new position in Axsome Therapeutics during the fourth quarter worth about $33,000. Quent Capital LLC acquired a new position in Axsome Therapeutics in the 3rd quarter valued at about $54,000. Signaturefd LLC boosted its holdings in Axsome Therapeutics by 627.0% in the 4th quarter. Signaturefd LLC now owns 727 shares of the company’s stock valued at $56,000 after purchasing an additional 627 shares during the last quarter. Finally, Great West Life Assurance Co. Can purchased a new stake in shares of Axsome Therapeutics in the 3rd quarter valued at approximately $69,000. 59.71% of the stock is currently owned by hedge funds and other institutional investors.

About Axsome Therapeutics

(Get Rating)

Axsome Therapeutics, Inc is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14.